NCT01673711View on ClinicalTrials.gov

Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

CompletedOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2019

Study Completion Date

September 30, 2019

Conditions
Lung CancerSquamous Lung DysplasiaTobacco Use Disorder
Interventions
DRUG

deuterated phenanthrene tetraol

Given PO

DRUG

pharmacological study

Correlative studies

DRUG

laboratory biomarker analysis

Correlative studies

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

55905

Mayo Clinic, Rochester

V5Z 4E6

BC Cancer Agency, Vancouver

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Minnesota

OTHER

NCT01673711 - Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer | Biotech Hunter | Biotech Hunter